Incyte hits endpoint in 2nd pivotal atopic dermatitis trial

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Feb 19, 2020 at 10:22 AM.

  1. #1 cafead, Feb 19, 2020 at 10:22 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,990
    Likes Received:
    3
    via A second phase 3 trial of Incyte’s ruxolitinib cream in atopic dermatitis has met its primary endpoint. The back-to-back pivotal successes tee Incyte up to talk to regulators about bringing the JAK inhibitor to market.

    article source
     
    Quote

Reply to Thread